Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (331-340 of 358) with videos related to

Pageof 36
Sort By:
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Plos Pathogens|July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in AfricaBetty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Aging|August 14, 2020
Global variability of the human IgG glycomeJerko Štambuk, Natali Nakić, Frano Vučković, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Pageof 36

Showing results (331-340 of 358) with videos related to

Sort By:
Pageof 36
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Plos Pathogens|July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2024
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in AfricaBetty Mwesigwa, Fredrick Sawe, Janet Oyieko, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Aging|August 14, 2020
Global variability of the human IgG glycomeJerko Štambuk, Natali Nakić, Frano Vučković, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
Pageof 36